Tianjin Chuangyuan Biotechnology Co., Ltd.

Home page

All

All
Product Management
News
Introduction
Enterprise outlets
FAQ
Enterprise Video
Enterprise Atlas

Corporate News

Industry News

Learning Center

"Using bacteria to treat bacteria" | Research progress on the auxiliary treatment of Helicobacter pylori infection with probiotics.

Preface

Helicobacter pylori (Hp)is one of the globally prevalent pathogenic bacteria, and its infection can lead to many digestive system diseases, such as chronic active gastritis, gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer.

Currently, the first-line treatment for Hp is the proton pump inhibitor (PPI) combined with antibiotics 'triple therapy'. However, the clinical use of bismuth agents or PPIs combined with antibiotics not only causes gastrointestinal discomfort, nausea, and vomiting as side effects but also carries the risk ofincreased Hp resistance.Studies have found that the cure rate of antibiotics for Hp is declining year by year^[1].

In recent years, with the increasing research reports on probiotics' ability to inhibit Hp, and due to their advantages such as not causing increased resistance, they have attracted widespread attention from all sectors of society, and the exploration of probiotics in vivo, in vitro, and in clinical settings has gradually become comprehensive and in-depth.

Introduction to Helicobacter pylori

Helicobacter pylori (Hp)is a Gram-negative, microaerophilic, spiral-shaped, and flagellated bacterium that infects about half of the global population. It was discovered in 1983 by Barry J. Marshall and J. Robin Warren, who were awarded the Nobel Prize in Physiology or Medicine in 2005.

Many people are indifferent to Helicobacter pylori because their understanding of it is not deep enough.Helicobacter pylori poses great harm to humans; it has a particular affinity for humans, which are its natural hosts, residing in the stomach and the bulb of the duodenum.Helicobacter pylori is the only bacterium that can survive in gastric acid; the higher the concentration of gastric acid, the more it reproduces. It has flagella on both sides, giving it strong motility, allowing it to move rapidly in a spiral manner and spread between people through oral-oral, fecal-oral, and gastric-oral routes via the micro-mucosal layer.

Helicobacter pylori produces urease during its growth and reproduction, which reacts with urea in the stomach to generate ammonia. Ammonia reacts with reactive oxygen to produce stronger chloramines,eroding the gastric mucosa.The VacA protein released by Helicobacter pylori also erodes the surface cells of the gastric mucosa, causing damage to the gastric mucosa and inducing inflammation,which can gradually develop into gastric ulcers or even gastric cancer!

Helicobacter pylori infection is a major pathogenic factor for chronic active gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. In 1994, the World Health Organization/International Agency for Research on Cancer (WHO/IARC)classified Helicobacter pylori as a Group I carcinogen..

The issue of antibiotic resistance in the clinical treatment of Helicobacter pylori

ForHelicobacter pylori, there are mainly two treatment regimens in clinical practice:proton pump inhibitors(PPI) combined with two otherantibiotics in a triple therapy and a quadruple therapy containing bismuth agents.With the widespread use of antibiotics in the treatment of Helicobacter pylori, the number of resistant strains of Helicobacter pylori continues to increase, meaning that the strains' resistance to drugs is enhanced, leading to an increased failure rate of treatment, which affects the prognosis of various gastrointestinal diseases.^[2].

For the recommended antibiotics for treatment, the resistance rates of Helicobacter pylori are as follows: Metronidazole, 60%-70%; Clarithromycin, 20%-38%; Levofloxacin, 30%-38%; among which the resistance rates of Amoxicillin, Furazolidone, and Tetracycline remain very low (1%-5%).

The mechanism by which probiotics enhance the cure rate of Helicobacter pylori

In clinical practice, using probiotics to replace or reduce the use of antibiotics can not only reduce the colonization of Hp in the stomach and alleviate gastric inflammation but also reduce side effects and improve patient compliance. Probiotics play a positive role in the treatment of Hp through various regulatory mechanisms (Figure 1):

Figure 1 Possible mechanisms of probiotics in the treatment of Hp infection^[3]

1. Probiotics inhibit the colonization of Helicobacter pylori.

Hp mainly exerts its pathogenic effects by adhering to and colonizing the gastric mucosal tissue. Reducing Hp adhesion is an important mechanism to protect the gastric and duodenal lumen from inflammation and to prevent atrophic gastritis, which can lower its pathogenicity. On one hand, some metabolic products of probiotics can exert anti-adhesion activity, reducing Hp adhesion on cell surfaces. On the other hand, probiotics can adhere to gastric epithelial cells through their own strong adhesion, competing for binding sites with Hp, thereby inhibiting Hp colonization.^[1].

2.Probiotics enhance the mucosal barrier.

3. The metabolic products of probiotics inhibit the growth of Helicobacter pylori.

Research shows that probiotics can inhibit Hp growth by secreting metabolites such as lactic acid, short-chain fatty acids, hydrogen peroxide, and bacteriocins. Among them, lactic acid bacteria, Bacillus subtilis, and Bifidobacterium can all produce bacteriocins. The antibacterial substance Amicoumacin A produced by Bacillus subtilis not only inhibits pathogenic bacteria such as Shigella and Campylobacter jejuni but also inhibits 21 strains of Hp.^[1^]Research shows that Bacillus subtilis R-179 has a gene encoding the production of subtilosin A.^[4]Subtilosin A is a type of thiopeptide antibacterial substance, and the expression level of its precursor gene is positively correlated with the ability to resist Helicobacter pylori.^[5].

4. Probiotics regulate host immune responses.

Research has found that probiotics can enhance the function against H. pylori by modulating the immune response to pathogens. Probiotics regulate the immune response by interacting with epithelial cells, thereby altering the release of anti-inflammatory factors and alleviating the symptoms of gastritis. Probiotics can reduce the levels of inflammatory factors such as IL-1, IL-6, IL-8, and TNF-α, and mitigate the inflammatory response caused by H. pylori by inhibiting the Smad 7 pathway, NF-κB pathway, or JAK-STAT pathway.^[1]In addition, some probiotics can inhibit the pro-inflammatory functions of Th1 and Th17 cells and their cytokines, stimulate dendritic cells to form anti-inflammatory pathways, and stimulate B cells to produce IgA, enhancing the immune barrier and stabilizing mucosal function. The specific immune modulation process can be seen in Figure 1.

5. Probiotics maintain the natural microecological balance.

A large number of studies have confirmed that the microbiota is closely related to the occurrence and development of gastrointestinal diseases. Disruption of the gastric microbiota can even promote the development of gastric cancer. Therefore, during the treatment of H. pylori, the impact on the balance of the gastrointestinal microbiota should also be minimized. Probiotics can inhibit the colonization and growth of pathogenic bacteria such as H. pylori through strong adhesion and secretion of antibacterial substances. In addition, the organic acids produced by probiotics can help restore the stomach to a normal pH, making it difficult for many acid-sensitive pathogenic bacteria to survive.^[1].

In summary,probioticscan inhibit Helicobacter pylori to some extent through the bacteria themselves or their metabolic products, mainly achieved through various pathways such as competitive binding sites, production of antibacterial active substances, and regulation of inflammatory factors.

References:

1. Shang Yanyan, et al. Mechanisms and research progress of probiotics in inhibiting Helicobacter pylori [J/OL]. Acta Microbiologica Sinica: 1-21.

2. Kong Xiangye, Ouyang Jiandong. Research progress on the auxiliary treatment of Helicobacter pylori infection with probiotics [J]. World Medical Information Digest, 2017, 17(99): 63-64.

3. Eslami M, et al. Comp Immunol Microbiol Infect Dis. June 2019; 64: 99-108.

4. Liu Wei, et al. Advances in Modern Biomedical Science, 2021, 21(08): 1425-1429.

5. Yu Gang, et al. Journal of Drug Analysis, 2014, 34(10): 1902-1906.

(The article is extracted from popular science literature and does not provide any medical guidance.)

Some images and texts are sourced from the internet. If there is any infringement, please inform us for deletion.

hp, probiotics, Helicobacter pylori, antibiotics

Natural compounds affecting diabetes through gut microbiota (Part 1)

Why do dead bacteria still have health benefits? A detailed explanation of the five mechanisms of postbiotics.

Natural compounds affecting diabetes through gut microbiota (Part 1)

Why do dead bacteria still have health benefits? A detailed explanation of the five mechanisms of postbiotics.

2024-12-23

In December 2024, Tianjin Chuangyuan Biotechnology Co., Ltd. and Haihe Dairy jointly held a series of themed activities titled "Party Building Mutual Visits and Learning" to further promote the deep integration of both parties' party building work and business development. During the event, both sides will conduct company visits and on-site discussions. Recently, Haihe Dairy made an initial visit and, after gaining a deep understanding of Chuangyuan Biotech's products, expressed high recognition and close attention, laying a solid foundation for future cooperation. Subsequently, both parties engaged in detailed communication on the core topics of "exchange of party building experiences and sharing of business resources," discussing standardized construction of party branches, distinctive party building measures, and the promotion of party-business integration. They also conducted in-depth exchanges on aspects such as corporate cooperation, product intercommunication, and information sharing, jointly exploring new paths for the development of the health industry under the guidance of party building, providing more possibilities for further establishing a "symbiotic, mutually promoting, and win-win" cooperative relationship. Both parties hope to achieve industrial resonance through party building leadership and contribute to the development of the health industry in the Binhai New Area.

Strength crowned, Chuangyuan Biotechnology won two Science and Technology Awards from the China Food Industry Association.

2024-12-17

On December 16, 2024, the 22nd China Food Safety Conference and the 2024 National Food Industry Science and Technology Progress Conference, themed "Implementing Food Safety Strategy to Support the Construction of a Healthy China," was grandly held in Beijing. During the conference, the award ceremony for the 2024 National Food Industry Science and Technology Progress Conference was also held. Tianjin Chuangyuan Biotechnology Co., Ltd. won the second prize for scientific and technological progress in the "2023 China Food Industry Association Science and Technology Award" for two projects: "Key Technology Breakthrough and Industrial Application of New Postbiotics Segmented Solid-State Fermentation" and "Development and Application of Key Technologies and Equipment for Plant Polysaccharide Efficacy Verification and Extraction."

Chuangyuan Biotech's lactic acid bacteria IOB701 post-fermentation probiotic powder has been granted a national invention patent.

2024-12-13

On December 13, 2024, Tianjin Chuangyuan Biotechnology Co., Ltd. received an invention patent certificate from the National Intellectual Property Administration for its independently developed and filed method and application for the preparation of Lactobacillus plantarum IOB701 fermented postbiotics powder (Patent No.: ZL 202411354886.X). This invention provides a method and application for the preparation of Lactobacillus plantarum IOB701 fermented postbiotics powder, which relates to the field of microbiology. The Lactobacillus plantarum IOB701 was preserved on July 10, 2018, at the General Microbial Culture Collection Center of the China Microbial Strain Preservation Management Committee, abbreviated as CGMCC, with the preservation address at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number CGMCC No. 16077. Using grains or legumes treated with low oxygen stress as the fermentation substrate, the Lactobacillus plantarum IOB701 fermentation resulted in postbiotics powder, which, according to animal experiments, has been shown to improve chronic unpredictable mild stress-induced depressive-like behavior in mice.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Jin Gong Wang An Bei No. 12019202000539

Business License